September 23, 2022
A Massachusetts federal judge has trimmed biotechnology company Atum's fraud and mismanagement counterclaims in rival SalioGen's trade secrets suit against it over genomics technology, but allowed Atum's arguments over the ownership of those trade secrets to proceed since a substantial controversy exists.